Potential genetic influences on the response to asthma treatment

Pulmonary Pharmacology and Therapeutics

Volumn 17, Issue 5, 2004, Pages 253-261

  Pelaia, Girolamo ^a   Vatrella, Alessandro ^b   Gallelli, Luca ^a   Cazzola, Mario ^c   Maselli, Rosario ^a   Marsico, Serafino A ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c CARDARELLI HOSPITAL   (Italy)

Author keywords

Asthma; Drug targets; Pharmacogenetics; Polymorphisms

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLSALICYLIC ACID; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE; ATRELEUTON; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DEXAMETHASONE; FORMOTEROL; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HISTONE DEACETYLASE; IMIDAZOLE DERIVATIVE; LEUKOTRIENE; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; METHACHOLINE; METHYLXANTHINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MONTELUKAST; MUSCARINIC RECEPTOR; SALBUTAMOL; SALMETEROL; ZAFIRLUKAST; ZILEUTON;

ASTHMA; BRONCHODILATING ACTIVITY; DRUG TARGETING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; WILD TYPE;

EID: 5144230472     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pupt.2004.04.005     Document Type: Article

References (81)

1. Weiss K.B., Sullivan S.D. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol. 107:2001;3-8
2. Hall I.P. Pharmacogenetics of asthma. Eur Respir J. 15:2000;449-451
3. Drazen J.M., Silverman E.K., Lee T.H. Heterogeneity of therapeutic responses in asthma. Br Med Bull. 56:2000;1054-1070
4. Palmer L.J., Silverman E.S., Weiss S.T., Drazen J.M. Pharmacogenetics of asthma. Am J Respir Crit Care Med. 165:2002;861-866
5. Brookes A.J. The essence of SNPs. Gene. 8:1999;177-186
6. Small K.M., McGraw D.W., Liggett S.B. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol. 43:2003;381-411
7. Dewar J.C., Hall I.P. Personalized prescribing for asthma - is pharmacogenetics the answer? J Pharm Pharmacol. 55:2003;279-289
8. 2 adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol. 8:1993;334-339
9. 2-adrenergic receptor and asthma. Am J Respir Crit Care Med. 156:1997;S156-S162
10. Fenech A., Hall I.P. Pharmacogenetics of asthma. Br J Clin Pharmacol. 53:2002;3-15
11. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 33:1994;9414-9419
12. 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol. 13:1995;25-33
13. 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet. 350:1997;995-999
14. 2- adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. J Allergy Clin Immunol. 101:1998;337-341
15. 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest. 100:1997;3184-3188
16. 2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther. 65:1999;519-525
17. 2-agonist therapy in asthma. Eur Respir J. 11:1998;589-593
18. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 162:2000;75-80
19. 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet. 345:1995;1213-1214
20. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem. 268:1993;23116-23121
21. 2-adrenergic receptor structure. Pulm Pharmacol. 8:1995;1-10
22. 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci USA. 93:1996;10483-10488
23. 2-adrenergic receptor mRNA inhibits receptor synthesis. J Biol Chem. 269:1994;4497-4505
24. 2-adrenergic receptor regulate receptor expression. J Clin Invest. 102:1998;1927-1932
25. 2- adrenergic gene. Br J Pharmacol. 126:1999;841-844
26. 2-adrenergic receptors: relevance to asthma. J Allergy Clin Immunol. 105:2000;S487-S492
27. 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA. 97:2000;10483-10488
28. Barnes P.J., Greening A.P., Crompton G.K. Glucocorticoid resistance in asthma. Am J Respir Crit Care Med. 152:1995;S125-S140
29. Beato M., Klug J. Steroid hormone receptors: an update. Hum Reprod Update. 6:2000;225-236
30. Bamberger C.M., Schulte H.M., Chrousos G.P. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocrinol Rev. 17:1996;245-261
31. Rivers C., Levy A., Hancock J., Lighman S., Norman M. Insertion of an amino acid in the DNA-binding domain of the glucocorticoid receptor as a result of alternative splicing. J Clin Endocrinol Metab. 84:1999;4283-4286
32. Holloway J.W., Jongepier H., Beghè B., Koppelman G.H., Holgate S.T., Postma D.S. The genetics of asthma. Eur Respir Mon. 23:2003;26-56
33. Leung D.Y.M., Hamid Q., Vottero A., Szefler S.J., Surs W., Minshall E., Chrousos G.P., Klemm D.J. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor β J Exp Med. 186:1997;1567-1574
34. Gagliardo R., Chanez P., Vignola A.M., Bousquet J., Vachier I., Godard P., Bonsignore G., Demoly P., Mathieu M. Glucocorticoid receptor α and β in glucocorticoid dependent asthma. Am J Respir Crit Care Med. 162:2000;7-13
35. Tissing W.J.E., Meijering J.P.P., den Boer M.L., Pieters R. Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia. 17:2003;17-25
36. Koper J.W., de Stolk R.P., Lange P., Pols H.A., Stolk R.P., Burger H., Grobbee D.E., Brinkmann A.O., De Jong F.H., Lamberts S.W. Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum Genet. 99:1997;663-668
37. Ruiz M., Lind U., Gavfels M., Eggerston G. Characterisation of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance. Clin Endocrinol. 55:2001;363-371
38. Hurley D.M., Accili D., Stratakis C.A. Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest. 87:1991;680-686
39. Malchoff D.M., Brufsky A., Reardon G. A mutation of the glucocorticoid receptor in primary cortisol resistance. J Clin Invest. 91:1993;1918-1925
40. Huizenga N.A., Koper J.W., de Lange P. A polymorphism in the glucocorticoid receptor gene may be associated with an increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab. 83:1998;144-151
41. Lane S.J., Arm J.P., Staynov D.Z., Lee T.H. Chemical mutational analysis of the human glucocorticoid receptor cDNA in glucocorticoid resistant bronchial asthma. Hum Genet. 11:1994;42-48
42. Ito K., Barnes P.J., Adcock I.M. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1β-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol. 20:2000;6891-6903
43. Pelaia G., Vatrella A., Cuda G., Maselli R., Marsico S.A. Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases. Life Sci. 72:2003;1549-1561
44. Fischer D.D., Cai R., Bhatia U., Asselbergs F.A., Song C., Terry R., Trogani N., Widmer R., Atadja P., Cohen D. Isolation and characterization of a novel class II histone deacetylase, HDAC10. J Biol Chem. 277:2002;6656-6666
45. Pelaia G., Cuda G., Vatrella A., Fratto D., Tagliaferri P., Maselli R., Costanzo F.S., Marsico S.A. Mitogen-activated protein kinases: new molecular targets for pharmacological treatment of inflammatory lung diseases. Curr Med Chem - Anti-Inflamm Anti-Allergy Agents. 2:2003;131-141
46. Pelaia G., Cuda G., Vatrella A., Grembiale R.D., De Sarro G.B., Maselli R., Costanzo F.S., Avvedimento V.E., Rotiroti D., Marsico S.A. Effects of glucocorticoids on activation of c-Jun N-terminal, extracellular signal-regulated, and p38 MAP kinases in human pulmonary endothelial cells. Biochem Pharmacol. 62:2001;1719-1724
47. Pelaia G., Cuda G., Vatrella A., Grembiale R.D., Fratto D., Tagliaferri P., Maselli R., Costanzo F.S., Marsico S.A. Effects of transforming growth factor-β and budesonide on mitogen-activated protein kinase activation and apoptosis in airway epithelial cells. Am J Respir Cell Mol Biol. 29:2003;12-18
48. Barnes P.J. Cytokine modulators as novel therapies for asthma. Annu Rev Pharmacol Toxicol. 42:2002;81-98
49. English J., Pearson G., Wilsbacher J., Swantek J., Karandikar M., Xu S., Cobb M.H. New insights into the control of MAP kinase pathways. Exp Cell Res. 253:1999;255-270
50. Irusen E., Matthews J.G., Takahashi A., Barnes P.J., Chung K.F., Adcock I.M. p38 mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol. 109:2002;649-657
51. Rogatsky I., Logan S.K., Garabedian M.J. Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. Proc Natl Acad Sci USA. 95:1998;2050-2055
52. Bantel H., Schmitz M.L., Raible A., Gregor M., Schulze-Osthoff K. Critical role of NF-κB and stress-activated protein kinases. FASEB J. 16:2002;1832-1834
53. Pfahl M. Nuclear receptor/AP-1 interaction. Endocrinol Rev. 14:1993;651-658
54. Ray A., Prefontaine K.E. Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Proc Natl Acad Sci USA. 91:1994;752-756
55. Barnes P.J., Adcock I.M. Transcription factors and asthma. Eur Respir J. 12:1998;221-234
56. Adcock I.M. Steroid resistance in asthma: molecular mechanisms. Am J Respir Crit Care Med. 154:1996;S58-S61
57. Lane S.J., Adcock I.M., Richards D., Hawrylowicz C., Barnes P.J., Lee T.H. Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes. J Clin Invest. 102:1998;2156-2164
58. Umino Y., Hohjoh H., Tokunaga K. Novel single nucleotide polymorphisms (SNPs) at positions 497 (T/G)Q and 829 (T/C) in the human c-fos gene and haplotype association. Hum Mutat. 16:2000;279
59. Wechsler M.E., Israel E. Pharmacogenetics of treatment with leukotriene modifiers. Curr Opin Allergy Clin Immunol. 2:2002;395-401
60. In K.H., Asano K., Bejer D., Grobholz J. Naturally occurring mutations in the human 5-lipoxygenase gene promoter which modify transcription factor binding and reporter gene transcription. J Clin Invest. 99:1997;1130-1137
61. Silverman E.S., Du J., De Sanctis G.T., Radmark O., Samuelsson B., Drazen J.M., Collins T. Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants. Am J Respir Cell Mol Biol. 19:1998;316-323
62. Drazen J.M., Yandava C.N., Dubé L., Szczerback N., Hippensteel R., Pillari A., Israel E., Schork N., Silverman E.S., Katz D.A., Drajesk J. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet. 22:1999;168-170
63. Anderson W., Kalberg C., Edwards L., Fling M., Binnie C., Nguyen Q., Sherman P., Sprankle K., Wagner M., Rickard K., Manasco P. Effects of polymorphisms in the promoter region of 5-lypoxygenase and LTC4 synthase on the clinical response to zafirlukast and fluticasone. Eur Respir J. 16:(Suppl B):2000;183s
64. 4 synthase promoter polymorphism and risk of aspirin induced asthma. Lancet. 350:1997;1599-1600
65. 4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest. 101:1998;834-846
66. 4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol. 23:2000;290-296
67. 4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax. 55:(Suppl 2):2000;S28-S31
68. 4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J Allergy Clin Immunol. 106:2000;72-76
69. Sayers I., Barton S., Rorke S., Beghè B., Hayward B., Van Eerdewegh P., Keith T., Clough J.B., Ye S., Holloway J.W., Sampson A.P., Holgate S.T. Allelic association and functional studies of promoter polymorphism in the leukotriene C4 synthase gene (LTC4S) in asthma. Thorax. 58:2003;417-424
70. Page C.P. Recent advances in our understanding of the use of theophylline in the treatment of asthma. J Clin Pharmacol. 39:1999;237-240
71. Torphy T.J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med. 157:1998;351-370
72. Ito K., Lim S., Caramori G., Cosio B., Chung K.F., Adcock I.M., Barnes P.J. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA. 2002;8921-8926
73. 3 receptor genes in normal and asthmatic subjects. Br J Pharmacol. 133:2001;43-48
74. Yamamoto T., Yamashita N., Kuwabara M., Nakano J., Sugimoto H., Akiyama K., Hirai K., Ishii A., Uehara Y., Ohta K. Mutation screening of the muscarinic m2 and m3 receptor genes in asthmatics, outgrow subjects, and normal controls. Ann Genet. 45:2002;109-113
75. Fenech A.G., Billington C.K., Swan C., Richards S., Hunter T., Ebejer M.J., Felice A.E., Ellul-Micallef R., Hall I.P. Novel polymorphisms influencing transcription of the human CHRM2 gene in airway smooth muscle. Am J Respir Cell Mol Biol. 30:2004;678-686
76. Chiba M., Xu X., Nishime J.A., Balani S.K., Lin J.H. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab Dispos. 25:1997;1022-1031
77. Zhang Z.Y., Kaminsky L.S. Characterisation of the human cytochromes p450 involved in theophylline 8-hydroxylation. Biochem Pharmacol. 50:1995;205-211
78. Johnsson G., Astrom A., Andersson P. Budesonide is metabolised by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos. 23:1995;137-142
79. Manchee G.R., Eddershaw P.J., Ranshaw L.E. The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsome is catalysed by CYP3A. Drug Metab Dispos. 24:1996;555-559
80. Kimura M., Ieiri I., Mamiya K., Urae A., Higuchi S. Genetic polymorphism of cytochrome p450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit. 20:1998;243-247
81. Ieiri I., Tainaka H., Morita T. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single strand conformational polymorphism analysis. Ther Drug Monit. 22:2000;237-244